Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Gene expression analysis of cultured amniotic fluid cell with Down syndrome by DNA microarray.

Authors: Chung, In-Hyuk  Lee, Sook-Hwan  Lee, Kyo-Won  Park, Sang-hee  Cha, Kwang-Yul  Kim, Nam-Soon  Yoo, Hyang-Sook  Kim, Yong Sung  Lee, Suman 
Citation: Chung IH, etal., J Korean Med Sci. 2005 Feb;20(1):82-7. doi: 10.3346/jkms.2005.20.1.82.
Pubmed: (View Article at PubMed) PMID:15716609
DOI: Full-text: DOI:10.3346/jkms.2005.20.1.82

Complete or partial triplication of human chromosome 21 results in Down syndrome (DS). To analyze differential gene expressions in amniotic fluid (AF) cells of DS, we used a DNA microarray system to analyze 102 genes, which included 24 genes on chromosome 21, 28 genes related to the function of brain and muscle, 36 genes related to apoptosis, 4 genes related to extracellular matrix, 8 genes related to other molecular function and 2 house-keeping genes. AF cells were collected from 12 pregnancies at 16-18 weeks of gestation in DS (n=6) and normal (n=6) subjects. Our DNA microarray experiments showed that the expressions of 11 genes were altered by at least 2-folds in DS, as follows. Ten genes, COL6A1, CASP5, AKT2, JUN, PYGM, BNIP1, OSF-2, PRSS7, COL3A1, and MBLL were down-regulated and GSTT1 was only up-regulated. The differential expressions of GSTT1 and COL3A1 were further confirmed by semi-quantitative RT-PCR for each sample. The gene dosage hypothesis on chromosome 21 may explain the neurological and other symptoms of DS. However, our results showed that only two genes (COL6A1 and PRSS7), among 24 genes on chromosome 21, were down-regulated in the AF cells of DS. Our data may provide the basis for a more systematic identification of biological markers of fetal DS, thus leading to an improved understanding of pathogenesis for fetal DS.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 14398459
Created: 2019-04-17
Species: All species
Last Modified: 2019-04-17
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.